Takehisa Hebishima
Overview
Explore the profile of Takehisa Hebishima including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
28
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kadengodlu P, Hebishima T, Takeshima S, Ito M, Liu M, Abe H, et al.
Int J Nanomedicine
. 2012 Oct;
7:5437-50.
PMID: 23091385
Purpose: Recombinant human gelatins with defined molecular weights were modified with cholesterol to make them amphiphilic in nature. We investigated the feasibility of these modified human gelatins acting as a...
2.
Hebishima T, Yuba E, Kono K, Takeshima S, Ito Y, Aida Y
Clin Vaccine Immunol
. 2012 Jul;
19(9):1492-8.
PMID: 22815149
We examined the ability of a novel liposome, surface modified by 3-methyl-glutarylated hyperbranched poly(glycidol) (MGlu-HPG), to enhance antigen-specific immunity in vitro and in vivo and to function as a vaccine...
3.
Induction of antigen-specific immunity by pH-sensitive carbonate apatite as a potent vaccine carrier
Hebishima T, Tada S, Takeshima S, Akaike T, Ito Y, Aida Y
Biochem Biophys Res Commun
. 2011 Nov;
415(4):597-601.
PMID: 22074821
The ability of carbonate apatite (CO(3)Ap) to enhance antigen-specific immunity was examined in vitro and in vivo to investigate its utility as a vaccine carrier. Murine bone marrow-derived dendritic cells...
4.
Hebishima T, Matsumoto Y, Watanabe G, Soma G, Kohchi C, Taya K, et al.
Exp Anim
. 2011 Apr;
60(2):101-9.
PMID: 21512265
To investigate the usefulness of the immunopotentiator from Pantoea agglomerans 1 (IP-PA1) as a supportive drug in melanoma therapy, we analyzed the immunological effects of IP-PA1 on melanoma-inoculated model mice....
5.
Hebishima T, Matsumoto Y, Watanabe G, Soma G, Kohchi C, Taya K, et al.
Anticancer Res
. 2010 Sep;
30(8):3113-8.
PMID: 20871028
Immunopotentiator from Pantoea agglomerans 1 (IP-PA1), an edible lipopolysaccharide (LPS) derived from symbiotic bacteria in crops, is a promising immunomodulator. It activates macrophages and protects from chemotherapeutic agent-induced growth inhibition...
6.
Hebishima T, Matsumoto Y, Watanabe G, Soma G, Kohchi C, Taya K, et al.
Anticancer Res
. 2010 Jul;
30(6):2033-40.
PMID: 20651348
Background: The immunopotentiator from Pantoea agglomerans 1 (IP-PA1) is an edible lipopolysaccharide (LPS) derived from symbiotic bacteria found in crops. IP-PA1 is known to ameliorate chemotherapy-induced immunosuppression; therefore, its macrophage-activating...
7.
Hebishima T, Matsumoto Y, Soma G, Kohchi C, Watanabe G, Taya K, et al.
J Vet Med Sci
. 2009 Dec;
72(4):435-42.
PMID: 20035113
Considering the usefulness of the immunopotentiator from Pantoea agglomerans 1 (IP-PA1), which is a purified lipopolysaccharide (LPS) derived from symbiotic gram-negative bacteria of food crops, in controlling immunosuppression in poultry...